

Supplemental Table 1 Review of the literature

| C | Reference^f | Dicer1 Syndromic^b | Dicer1 Non-syndromic^b | Number of cases (n)^h | Age^c | Gender | Size (mm)^e | Non-thyroid tumours | Histotype^g | Aggressive features | Multifocality/ Bilaterality^d | Encapsulation | Well- known somatic mutations |
|----------|------------------------------|---|---|--|--|-----------------|----------------------------------|--------------------------------|------------------------------|--------------------------------|--|----------------------|--|
| 2008 | 1-(Post-therapy) | DICER1 | NO | 1 | 6 | F | NA | PPB | FTC | recurrence, CI | NA | YES | NA |
| 2008 | 2 -(Post-therapy) | DICER1 | NO | 1 | 16 | F | NA | PPB, RMS, | miFTC and VA | CI | NA | YES | NA |
| 2010 | 3 ^f | NA | NA | 1 | 46 | F | 20 | SLCT | cystic PTC with oxyphillia | CI | NA | YES | NA |
| 2010 | 4 | DICER1 | NO | 3 | 34 | F (2), M (1) | NA | CN, PPB | MNG ^a | NA | NA | NA | NA |
| 2011 | 5 | DICER1 (1) | Germline pathogenic mutation (n=6) | 7 | 22 (syndromic cases)/ 9 (non- syndromic case) | NA | NA | SLCT, WT | MNG/cysyts ^a | NO | NA | NA | NA |
| 2011 | 6 | DICER1 (8) | Germline pathogenic mutation (n=31) | 39 | NA | NA | 16 (only syndromic ones) | SLCT (8 syndromic cases) | NA | NO | NA | NA | NA |
| 2012 | 7-Post-therapy) | NA | NA | 1 | 9 | F | 27 | PPB | FTC | CI | YES | YES | NO |
| 2013 | 8 | DICER1 | NO | 1 | 16 | F | NA | SLCT, CN, PB, ME | PTC | NA | NA | NA | NA |
| 2013 | 9 | DICER1 | NO | 2 | 18 | F | NA | SLCT | MNG | NA | YES | NA | NA |
| 2014 | 10 ^b | DICER1 | NO | 1 | 9 | M | 30 | CN | MNG | NO | YES | NA | NA |

| | | | | | | | | | | | | | |
|------|----|--------------|--|----|--|-----------------|----|---|--|-------------------------|-----|-----|----|
| 2014 | 11 | DICER1 | NO | 1 | 5 | F | NA | PPB, NCMH, CBME, ERMS, CN, SLCT | FV-PTC | NO | YES | YES | NA |
| 2014 | 12 | DICER1 | NO | 1 | 16 | F | NA | W DFA, SLCT, | MNG | NO | YES | NA | NA |
| 2014 | 13 | DICER1 | NO | 2 | 14 | F (1), M (1) | 40 | SLCT | MNG/ FA with PH | NO | YES | YES | NA |
| 2014 | 14 | DICER1 (1) | Germline pathogenic mutation (n=3) | 4 | 32 | F | NA | SLCT (1 syndromic case) | MNG | NA | YES | NA | NA |
| 2014 | 15 | DICER1 (3) | NO | 3 | 8.3 | F (2), M (1) | NA | PPB, cysyts, ME, cataract | FPTC (2), PTC | CI | NA | NA | NA |
| 2014 | 16 | DICER1 (5) | Germline pathogenic mutation (n=2) | 7 | 27 | F (3)/M (3) | NA | SLCT, CN, NCMH, PPB | PTC, DTC, MNG, Thyroid Cysts | NA | YES | NA | NA |
| 2015 | 17 | DICER1 | NO | 1 | 3 | F | NA | SLCT | PTC | NA | NA | NA | NA |
| 2016 | 18 | DICER1 (2) | Germline pathogenic mutation (n=3) | 5 | 11 | F | NA | SLCT, CN | EFV-PTC (3), miFTC (mother) | NO | YES | YES | NO |
| 2016 | 19 | NO | Somatic mutation | 4 | NA | NA | NA | NO | miFTC and FA | CI | NA | NA | NO |
| 2016 | 20 | DICER1 | NO | 2 | 14 | F | NA | OT, CP, L, CN, BCC, PM, ICT | MNG | NO | YES | NA | NA |
| 2016 | 21 | DICER1 | NO | 2 | 15 | F | 35 | SLCT, CN, ERMS, yolk sac, pituitary blastoma | EFV-PTC (1) and wi-FTC (1) | CI, VI (both in FTC) | YES | YES | NA |
| 2016 | 22 | DICER1 | NO | 1 | 11 | F | 10 | SLCT | HAN | NO | YES | YES | NA |
| 2016 | 23 | DICER1 | NO | 2 | 12 | F/M | NA | Uterine myoma, PPB | Thyroid cysts | NA | NA | NA | NA |
| 2017 | 24 | DICER1 | NO | 1 | 12 | F | 20 | ASK | mi FTC | CI | YES | YES | NA |
| 2017 | 25 | DICER1 (8Ma) | Germline pathogenic mutation (n=2Ma/12 Be) | 22 | 16 (syndromic), 36 (non- syndromic) | M (1), F (9) | NA | PPB, pineoblastoma | microPTC(1), FV-PTC(3), miFTC(1), FTC(1), mix pattern PTC(1), macrofollicular PTC(1), multifocal PTC(1), classical PTC(1) | CI | YES | YES | NA |
| 2017 | 26 | DICER1 | NO | 1 | 27 | F | NA | EAS | MNG | NA | NA | NA | NA |
| 2017 | 27 | NO | Germline pathogenic mutation (n=5 unaffected) | 5 | 23 (only 2 case) | F | NA | NO | MNG ^a | NA | YES | NA | NA |

| | | | carrier) | | available) | | | | | | | | |
|------|----|------------|--|----|---|--------------|----|-----------------------------|---|-----------------|--------------------------------|-----------|----------|
| 2018 | 28 | DICER1 | NO | 1 | 12 | F | 14 | Cervix ERMS | WDTC-NOS | AI | YES | Partially | NO |
| 2018 | 29 | NO | Somatic mutation | 1 | 45 | F | 28 | NO | TCS | DM, AI, CI | NA | NA | NO |
| 2018 | 30 | NO | Germline pathogenic (n=4) and somatic mutation (n=5) | 8 | <18 | F(7)/M(1) | 27 | NO | 6 PTC (2 aggressive subtype), IFV-PTC, miFV-PTC (9) and 2 FND | ALL, CI, AI (1) | YES (1) | YES (2) | NO |
| 2018 | 31 | DICER1 | NO | 10 | 29 | NA | NA | NCMH, SLCT, PPB, RMS, CN | DTC | NA | NA | NA | NA |
| 2018 | 32 | NO | Germline pathogenic mutation (n=10) somatic mutation (n=2) | 10 | 14 | F (7)/M (3) | T1 | Na | NIFTP (3), FV-PTC (5), PDTC (2) | NO | YES (6) | YES (3) | TP53 (1) |
| 2018 | 33 | NO | Somatic mutation | 1 | 11 | NA | 18 | NO | SV- PTC | NO | NO | YES | NO |
| 2018 | 34 | DICER1 | NO | 1 | 58 | F | NA | pituitary microprolactinoma | PTC | NA | NA | NA | NA |
| 2018 | 35 | DICER1 | NO | 1 | 13 | F | 70 | SLCT, ERMS | FV-PTC | NA | YES | NA | NA |
| 2018 | 36 | DICER1 (1) | Germline pathogenic mutation (n=6), somatic mutation (n=3) | 7 | <18(6), 23(1) | F (5)/M (2) | NA | SLCT (1 syndromic case) | MNG | NO | YES | NA | NA |
| 2019 | 37 | NO | Germline pathogenic mutation | 1 | 18 | F | NA | NO | FV-PTC | NA | NA | NA | NA |
| 2019 | 38 | DICER1 (5) | Germline pathogenic mutation (n=5) | 10 | 10.8 (syndromic cases)/ 15.4 (non-syndromic case) | F (7), M (3) | NA | SLCT, NB, cysts, ERMS | MNG | NO | 5 of them bilateral/multifocal | NA | NA |

Pleuropulmonary blastoma (PPB), Sertoli-Leydig cell tumour (SLCT), Embryonal rhabdomyosarcoma (ERMS), Wilms tumour(WT)nasal chondromesenchymal hamartoma (NCMH), medulla epithelioma (ME), Pineal blastoma (PB), ovarian teratoma (OT), colon polyps (CP), lymphoma (L), pilomatixoma (PM), intracranial teratoma (ICT), endometrial adenocarcinoma (EAS), anaplastic sarcoma of kidney (ASK), Well differentiated thyroid carcinoma (WDTC-NOS), thyroid carcinosarcoma (TCS), minimally invasive follicular thyroid carcinoma (miFTC),

follicular adenoma (FA), papillary thyroid carcinoma (PTC), invasive follicular variant papillary thyroid carcinoma (IFV-PTC), follicular nodular disease (FND), (NIFTP), poorly differentiated thyroid carcinoma (PDTC), Papillary hyperplasia (PH), multinodular goitre (MNG), vesicular adenoma (VA), encapsulated follicular variant of PTC (EFV-PTC), hyperplastic adenomatous nodule (HAN), solid variant of PTC (SV-PTC), widely invasive follicular thyroid carcinoma (wi-FTC), Angioinvasive (AI), capsule invasion (CI), distant metastasis (DM), vascular invasion (VI), acute lymphoblastic leukaemia (ALL). Malign (Ma), Benign (Be), Male (M), Female (F), NA: Non-available, NO: no

a-pathologically not proven (only radiologic finding)

b-The cases who has a family history, DICER1 germline alteration and at least 1 associated tumour previously reported in DICER1 syndrome were accepted as “syndromic”. Carriers or non-carriers without exposing multiple tumours (only with thyroid disease) were accepted as non-syndromic.

c-For the case series, mean age was calculated and both for the case series and isolated cases, the onset accepted according to the first manifestation of thyroid disease.

d-MNG was accepted as multifocal disease due to its nature

e-Mean size was calculated for the case series. Age was not separated syndromic versus non-syndromic when calculated for mean.

f-We tried to exclude the overlapping cases in the different articles.

g-Some cases have two peaks for thyroid disease, only the onset disease was noted when available

h-Not only index or issued cases but also probands/relatives were included when mentioned in the articles of the table.

REFERENCES:

1. Oue T, Inoue M, Kubota A, Kuwae Y, Kawa K. Pediatric thyroid cancer arising after treatment for pleuropulmonary blastoma. *Pediatr Blood Cancer*. 2008 Apr;50(4):901-2.
2. Rome A, Gentet JC, Coze C, André N. Pediatric thyroid cancer arising as a fourth cancer in a child with pleuropulmonary blastoma. *Pediatr Blood Cancer*. 2008 May;50(5):1081.
3. Poiana C, Virtej I, Carsote M, Banceanu G, Sajin M, Stanescu B, Ioachim D, Hortopan D, Coculescu M. Virilising Sertoli-Leydig cell tumour associated with thyroid papillary carcinoma: case report and general considerations. *Gynecol Endocrinol*. 2010 Aug;26(8):617-22.
4. Bahubeshi A, Bal N, Rio Frio T, Hamel N, Pouchet C, Yilmaz A, Bouron-Dal Soglio D, Williams GM, Tischkowitz M, Priest JR, Foulkes WD. Germline DICER1 mutations and familial cystic nephroma. *J Med Genet*. 2010 Dec;47(12):863-6.
5. Slade I, Bacchelli C, Davies H, Murray A, Abbaszadeh F, Hanks S, Barfoot R, Burke A, Chisholm J, Hewitt M, Jenkinson H, King D et al DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. *J Med Genet*. 2011 Apr;48(4):273-8.
6. Rio Frio T, Bahubeshi A, Kanellopoulou C, Hamel N, Niedziela M, Sabbaghian N, Pouchet C, Gilbert L, O'Brien PK. DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumours. *JAMA*. 2011 Jan 5;305(1):68-77.
7. Shin SH, Yoon JH, Son MH, Kim SJ, Park SY, Kim HY, Lee HS, Park HJ, Park BK. Follicular thyroid carcinoma arising after hematopoietic stem cell transplantation in a child with pleuropulmonary blastoma. *Thyroid*. 2012 May;22(5):547-51.
8. Ramasubramanian A, Correa ZM, Augsburger JJ, Sisk RA, Plager DA. Medulloepithelioma in DICER1 syndrome treated with resection. *Eye (Lond)*. 2013 Jul;27(7):896-7.
9. Darrat I, Bedoyan JK, Chen M, Schuette JL., Lesperance MM. A novel DICER1 mutation causes multi-nodular goiter in children. *Head Neck*. 2013 December; 35(12): E369-71
10. Rath SR, Bartley A, Charles A, Powers N, Baynam G, Jones T, Priest JR, Foulkes WD, Choong CS. Multinodular Goiter in children: an important pointer to a germline DICER1 mutation. *J Clin Endocrinol Metab*. 2014 Jun;99(6):1947-8.

11. Schultz KA, Yang J, Doros L, Williams GM, Harris A, Stewart DR, Messinger Y, Field A, Dehner LP, Hill DA. DICER1-pleuropulmonary blastoma familial tumour predisposition syndrome: a unique constellation of neoplastic conditions. *Pathol Case Rev.* 2014 Mar;19(2):90-100.
12. Wu Y, Chen D, Li Y, Bian L, Ma T, Xie M. DICER1 mutations in a patient with an ovarian Sertoli-Leydig tumour, well-differentiated fetal adenocarcinoma of the lung, and familial multinodular goiter. *Eur J Med Genet.* 2014 Nov-Dec;57(11-12):621-5.
13. Rossing M, Gerdes AM, Juul A, Rechnitzer C, Rudnicki M, Nielsen FC, Vo Hansen T1. A novel DICER1 mutation identified in a female with ovarian Sertoli-Leydig cell tumour and multinodular goiter: a case report. *J Med Case Rep.* 2014 Apr 3; 8:112.
14. Foulkes WD, Priest JR, Duchaine TF. DICER1: mutations, microRNAs and mechanisms. *Nat Rev Cancer.* 2014 Oct;14(10):662-72.
15. de Kock L, Sabbaghian N, Soglio DB, Guillerman RP, Park BK, Chami R, Deal CL, Priest JR, Foulkes WD. Exploring the association Between DICER1 mutations and differentiated thyroid carcinoma. *J Clin Endocrinol Metab.* 2014 Jun;99(6): E1072-7.
16. Sabbaghian N, Srivastava A, Hamel N, Plourde F, Gajtko-Metera M, Niedziela M, Foulkes WD. Germ-line deletion in DICER1 revealed by a novel MLPA assay using synthetic oligonucleotides. *Eur J Hum Genet.* 2014 Apr;22(4):564-7.
17. Puckett Y, Howe J, Vane D, Agarwal A, Batanian JR, Greenspon J. Case report of a 3-year-old girl with pleuropulmonary blastoma and family history of a tumour predisposition syndrome with c. 2830 gene mutation in DICER1. *J Ped Surg Case Reports* 3 (2015) 312e315
18. Rutter MM, Jha P, Schultz KA, Sheil A, Harris AK, Bauer AJ, Field AL, Geller J, Hill DA. DICER1 Mutations and Differentiated Thyroid Carcinoma: Evidence of a Direct Association. *J Clin Endocrinol Metab.* 2016 Jan;101(1):1-5.
19. Yoo SK, Lee S, Kim SJ, Jee HG, Kim BA, Cho H, Song YS, Cho SW, Won JK, Shin JY, Park do J, Kim JI, Lee KE, Park YJ, Seo JS. Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers. *PLoS Genet.* 2016 Aug 5;12(8): e1006239.
20. Mehraein Y, Schmid I, Eggert M, Kohlhase J, Steinlein OK. DICER1 syndrome can mimic different genetic tumour predispositions. *Cancer Lett.* 2016 Jan 28;370(2):275-8.

21. Durieux E, Descotes F, Mauduit C, Decaussin M, Guyetant S, Devouassoux-Shisheboran M. The co-occurrence of an ovarian Sertoli-Leydig cell tumour with a thyroid carcinoma is highly suggestive of a DICER1 syndrome. *Virchows Arch.* 2016 May;468(5):631-6
22. Canfarotta M, Riba-Wolman R, Orsey AD, Balarezod F, Fincke C. DICER1 syndrome and thyroid disease. *J Ped Surg Case Reports* 11 (2016) 31e34
23. Kuhlen M, Hönscheid A, Schemme J, Merz H, Mauz-Körholz C, Borkhardt A, Troeger A. Hodgkin lymphoma as a novel presentation of familial DICER1 syndrome. *Eur J Pediatr.* 2016 Apr;175(4):593-7.
24. Yoshida M, Hamanoue S, Seki M, Tanaka M, Yoshida K, Goto H, Ogawa S, Takita J, Tanaka Y. Metachronous anaplastic sarcoma of the kidney and thyroid follicular carcinoma as manifestations of DICER1 abnormalities. *Hum Pathol.* 2017 Mar; 61:205-209.
25. Khan NE, Bauer AJ, Schultz KAP, Doros L, Decastro RM, Ling A, Lodish MB, et al. Quantification of Thyroid Cancer and Multinodular Goiter Risk in the DICER1 Syndrome: A Family-Based Cohort Study. *J Clin Endocrinol Metab.* 2017 May 1;102(5):1614-1622.
26. Mullen MM, Divine LM, Hagemann IS1, Babb S, Powell MA. Endometrial adenosarcoma in the setting of a germline DICER1 mutation: A case report. *Gynecol Oncol Rep.* 2017 Apr 11; 20:121-124.
27. Cai S, Wang X, Zhao W, Fu L, Ma X, Peng X. DICER1 mutations in twelve Chinese patients with pleuropulmonary blastoma. *Sci China Life Sci.* 2017 Jul;60(7):714-720.
28. Gullo I, Batista R, Rodrigues-Pereira P, Soares P, Barroca H, do Bom-Sucesso M, Sobrinho-Simões M. Multinodular Goiter Progression Toward Malignancy in a Case of DICER1 Syndrome: Histologic and Molecular Alterations. *Am J Clin Pathol.* 2018 Mar 29;149(5):379-386.
29. Yang J, Sarita-Reyes C, Kindelberger D, Zhao Q. A rare malignant thyroid carcinosarcoma with aggressive behavior and DICER1 gene mutation: a case report with literature review. *Thyroid Res.* 2018 Jul 31;11:11.
30. Wasserman JD, Sabbaghian N, Fahiminiya S, Chami R, Mete O, Acker M, Wu MK, Shlien A, de Kock L, Foulkes WD. DICER1 Mutations Are Frequent in Adolescent-Onset Papillary Thyroid Carcinoma. *J Clin Endocrinol Metab.* 2018 May 1;103(5):2009-2015.

31. Stewart DR, Best AF, Williams GM, Harney LA, Carr AG, Harris AK, Kratz CP, Dehner LP, Messinger YH, Rosenberg PS, Hill DA, Schultz KAP. Neoplasm Risk Among Individuals with a Pathogenic Germline Variant in DICER1. *J Clin Oncol*. 2019 Mar 10;37(8):668-676.
32. van der Tuin K, de Kock L, Kamping EJ, Hannema SE, Pouwels MM, Niedziela M, van Wezel T, Hes FJ, Jongmans MC, Foulkes WD, Morreau H. Clinical and Molecular Characteristics May Alter Treatment Strategies of Thyroid Malignancies in DICER1 Syndrome. *J Clin Endocrinol Metab*. 2019 Feb 1;104(2):277-284
33. Ravella L, Lopez J, Descotes F, Lifante JC, David C, Decaussin-Petrucci M. [DICER1 mutated, solid/trabecular thyroid papillary carcinoma in an 11-year-old child]. *Ann Pathol*. 2018 Oct;38(5):316-320.
34. Cotton E, Ray D. DICER1 mutation and pituitary prolactinoma. *Endocrinol Diabetes Metab Case Rep*. 2018 Sep 25;2018.
35. Moke DJ, Thomas SM, Hiemenz MC, Nael A, Wang K, Shillingford N, Biegel JA, Mascarenhas L. Three synchronous malignancies in a patient with DICER1 syndrome. *Eur J Cancer*. 2018 Apr; 93:140-143
36. Apellaniz-Ruiz M, de Kock L, Sabbaghian N, Guaraldi F, Ghizzoni L, Beccuti G, Foulkes WD1. Familial multinodular goiter and Sertoli-Leydig cell tumours associated with a large intragenic in-frame DICER1 deletion. *Eur J Endocrinol*. 2018 Feb;178(2): K11-K19
37. Herriges JC, Brown S, Longhurst M, Ozmore J, Moeschler JB, Janze A et al. Identification of two 14q32 deletions involving DICER1 associated with the development of DICER1-related tumours. *Eur J Med Genet*. 2019 Jan;62(1):9-14.
38. de Kock L, Hillmer M, Wagener R, Soglio DB, Sabbaghian N, Siebert R, Priest JR, Miller M7, Foulkes WD. Further evidence that full gene deletions of DICER1 predispose to DICER1 syndrome. *Genes Chromosomes Cancer*. 2019 Aug;58(8):602-604